학술논문

IBCL-081 MAGNIFY Phase 3b Study of Lenalidomide + Rituximab (R2) Followed by Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Complete Induction Phase Analysis
Document Type
Article
Source
In: Clinical Lymphoma, Myeloma and Leukemia, Proceedings of the Society of Hematologic Oncology 2022 Annual Meeting. (Clinical Lymphoma, Myeloma and Leukemia, October 2022, 22:S384)
Subject
Language
English
ISSN
21522669
21522650